Sigumir
Sigumir (Ala-Glu-Asp-Gly)
A tetrapeptide bioregulator derived from cartilage and bone tissue. Part of the Russian peptide bioregulator series. Supports joint health and cartilage repair.
Mechanism of Action
Sigumir modulates gene expression in chondrocytes and osteoblasts, supporting cartilage matrix synthesis, reducing joint inflammation, and promoting bone and cartilage health.
Health Claims & Evidence
Supports cartilage health and joint function
Reduces joint inflammation
Supports bone health
Short-Term Effects
Potential improvements in joint comfort and mobility.
Long-Term Effects
Theoretical cartilage protection with repeated courses.
Side Effects
Extremely well-tolerated.
Contraindications
Limited data.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Sigumir and cartilage bioregulation
Khavinson et al. · Bulletin of Experimental Biology and Medicine · 2016
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Sigumir and related peptides, and prepare an educational research summary.
Explore Research